aviscera bioscience  
AVISCERA BIOSCIENCE
 
line decor
  HOME  ::  
line decor
   
 
CD5L (Soluble) ELISA Kit
CD5 Like (Soluble) ELISA Kit
A biomarker for Cardiovascular Diseases and Obesity
 
Infiltration of inflammatory macrophages into adipose tissues with the progression of obesity triggers insulin resistance and obesity-related metabolic diseases. We recently reported that macrophage-derived apoptosis inhibitor of macrophage (AIM) protein is increased in blood in line with obesity progression and is incorporated into adipocytes, thereby inducing lipolysis in adipose tissue. Here we show that such a response is required for the recruitment of adipose tissue macrophages. In vitro, AIM-dependent lipolysis induced an efflux of palmitic and stearic acids from 3T3-L1 adipocytes, thereby stimulating chemokine production in adipocytes via activation of toll-like receptor 4 (TLR4). In vivo administration of recombinant AIM to TLR4-deficient (TLR4(-/-)) mice resulted in induction of lipolysis without chemokine production in adipose tissues. Consistently, mRNA levels for the chemokines that affect macrophages were far lower in AIM-deficient (AIM(-/-)) than in wild-type (AIM(+/+)) obese adipose tissue. This reduction in chemokine production resulted in a marked prevention of inflammatory macrophage infiltration into adipose tissue in obese AIM(-/-) mice, although these mice showed more advanced obesity than AIM(+/+) mice on a high-fat diet. Diminished macrophage infiltration resulted in decreased inflammation locally and systemically in obese AIM(-/-) mice, thereby protecting them from insulin resistance and glucose intolerance. These results indicate that the increase in blood AIM is a critical event for the initiation of macrophage recruitment into adipose tissue, which is followed by insulin resistance. Thus, AIM suppression might be therapeutically applicable for the prevention of obesity-related metabolic disorders.
Kurokawa J et al. Proc Natl Acad Sci U S A. 2011 Jul 19;108(29):12072-7. 

Protein Biomarkers of New-Onset Cardiovascular Disease: Prospective Study From the Systems Approach toBiomarker Research in Cardiovascular Disease Initiative.

APPROACH AND RESULTS: We used discovery mass spectrometry (MS) to determine plasma concentrations of 861 proteins in 135 myocardial infarction (MI) cases and 135 matched controls. Then, we measured 59 markers by targeted MS in 336 ASCVD case-control pairs. Associations with MI or ASCVD were tested in single-marker and multiple-marker analyses adjusted for established ASCVD risk factors. Twelve single markers from discovery MS were associated with MI incidence (at P<0.01), adjusting for clinical risk factors. Seven proteins in aggregate (cyclophilin A, CD5 antigen-like, cell-surface glycoprotein MUC18, collagen-α 1 [XVIII] chain, salivary α-amylase 1, C-reactive protein, and multimerin-2) were highly associated with MI (P<0.0001) and significantly improved its prediction compared with a model with clinical risk factors alone (C-statistic of 0.71 versus 0.84). Through targeted MS, 12 single proteins were predictors of ASCVD (at P<0.05) after adjusting for established risk factors. In multiple-marker analyses, 4 proteins in combination (α-1-acid glycoprotein 1, paraoxonase 1, tetranectin, and CD5 antigen-like) predicted incident ASCVD (P<0.0001) and moderately improved the C-statistic from the model with clinical covariates alone (C-statistic of 0.69 versus 0.73).
Yin X, et al. Arterioscler Thromb Vasc Biol. 2014 Feb 13
Mouse Soluble CD5L ELISA Kit
Code No.: SK00493-01
Size: 96 T
Price: $460.00
Standard range:15.6-1000 pg/ml
Sensitivity: 3 pg/ml
Sample Type:serum, plasma
Sample require: 100 ul per well
Intra-CV:4-6%
Inter-CV: 8-12%
Data Sheet: PDF

 

Name
Code
Size
Price ($)

Soluble CD5L (Mouse) ELISA Kit

96 T

460.00

Soluble CD5L (Human) Rec. (293 cells derived)
00493-02-50
50 ug
290.00
Soluble CD5L (Human) Rec. (293 cells derived)
00493-02-100
100 ug
inquire